The t(3;21) chromosomal translocation seen in blastic crisis of chronic myeloid leukemia and secondary leukemias results in a formation of a chimeric protein AML1-Evi-1, which suppresses wild-type AML1 function. Loss of AML1 function causes expansion of hematopoietic progenitor cells, whereas it is not sufficient for the development of leukemia. To identify essential mechanisms through which AML1-Evi-1 exerts full leukemogenic potential, we introduced AML1-Evi-1 and its mutants in murine bone marrow cells, and evaluated their transforming activities by colony replating assays. The transforming activity of AML1-Evi-1 was lost when any of the known functional domains of Evi-1 was deleted from the chimeric protein, and forced expression of Evi-1 did not transform the AML1-deleted bone marrow cells. Unlike the MLL-ENL and AML1-ETO leukemia-related chimeric proteins, AML1-Evi-1 could transform only the hematopoietic stem cell fraction. Moreover, AML1-Evi-1-transformed cells show a cell-marker profile distinct from that of the cells transformed by AML1-ETO, which also suppresses AML1 function. Thus, leukemogenic activity of AML1-Evi-1 may be due to activation of molecular mechanisms distinct from those activated by MLL-ENL or AML1-ETO in the hematopoietic stem cell fractions.
Introduction
Chromosomal translocations involving AML1 (RUNX1), initially identified in t(8;21)(q22;q22) translocation found in the human acute myelogenous leukemia, 1,2 form in its in-frame fusion with a variety of chimeric proteins. AML1-related chimeric proteins found in leukemias include AML1-Evi-1 generated in t(3;21)(q26;q22) translocation.
3,4 AML1-Evi-1 is constituted from the N-terminal AML1-derived part that contains the evolutionarily conserved domain with DNA-binding capacity (Runt domain) and the C-terminal part in which the entire sequence of Evi-1 is fused to AML1 part in an in-frame manner. AML1-Evi-1 acts dominant negatively over the normal AML1 function by binding to the AML1-binding motif (PEBP2 sequence) in the target DNA. 5, 6 Therefore, repression of AML1 functions by the expression of chimeric genes may play a key role in leukemogenesis. By analyzing conditional knockout mice in which AML1 is deleted in adults, we and others have shown that loss of AML1 causes expansion of the most primitive hematopoietic stem/progenitor cells in adult hematopoiesis, [7] [8] [9] suggesting that loss of AML1 function is associated with expansion of leukemic cells. In accordance with this, expression of AML1-ETO, a product of t(8;21) that also represses normal AML1 function, 10 in the bone marrow cells of mice results in accumulation of the most immature hematopoietic stem/ progenitor cells. [11] [12] [13] However, whereas expression of AML1-Evi-1 transforms murine bone marrow cells, 14, 15 deletion of AML1 alone does not immortalize the bone marrow cells, 8 suggesting that the Evi-1 moiety of the chimeric protein has a key role in AML1-Evi-1 leukemogenesis.
Expression of Evi-1 can cause cell proliferation or block of apoptosis in leukemogenesis. Evi-1, a member of PRDI-BFI and RIZ homologous (PR) domain proteins, has been reported to have several functional domains. There are two major alternative forms generated from EVI-1 gene, Evi-1a and Evi-1c (also called MDS1-Evi-1). In contrast to Evi-1a, Evi-1c possesses the PR domain in the N-terminus, which regulates oligomerization of the Evi-1 proteins. 16 Evi-1a bears two zinc-finger domains, one of which is located at the N-terminus, and the other at the C-terminal region distal to the C-terminal binding protein (CtBP)-binding domain and the small repression domains (Figure 1a) . While the first zinc finger and the repression domains exhibit anti-growth repression effect by blocking transforming growth factor-b signaling, 17 the first zinc-finger domain also exhibits antiapoptotic effect by repressing c-Jun N-terminal kinase signaling, 18 and the second zinc-finger domain stimulates proliferation by increasing activator protein-1 activity. 19 The CtBP-binding domain at the middle of the protein binds to a member of the repressor complex, CtBP, [20] [21] [22] and is also involved in repression of transforming growth factorb-responsive transcription. 22 Many of these properties of Evi-1 are shared with AML1-Evi-1, 5, 23, 24 and is presumably related with leukemic cell proliferation.
Retroviral transduction of AML1-Evi-1 into murine bone marrow cells causes elongated replatability of the cells, and transduced cells cause leukemia in transplanted mice. 14 However, murine bone marrow cells transduced with Evi-1 alone cannot cause leukemia 25 and deletion of AML1 alone does not immortalize the bone marrow cells. 8 These findings suggest that suppression of AML1 and activation of Evi-1 are both required for AML1-Evi-1 leukemogenesis, but their roles have not been thoroughly elucidated. Moreover, it has not been reported which fraction of the bone marrow cells are immortalized by AML1-Evi-1. It is known that some leukemiainducible fusion genes can immortalize myeloid-committed progenitors, whereas others can immortalize only the hematopoietic stem cells (HSCs), and that the in vitro replating capacities are required for the development of leukemia when transplanted into mice. 26, 27 We here show that AML1-Evi-1 specifically transforms the HSC fraction of mice in contrast to AML1-ETO and MLL-ENL and that this transformation requires the multiple functional domains of Evi-1 moiety as well as the N-terminal AML1 portion.
Materials and methods

Plasmid construction
FLAG-tagged cDNA of Evi-1a, Evi-1c, AML1-Evi-1, 16 AML1-ETO (generous gift from Scott W Hiebert) 28 and MLL-ENL (generous gift from Toshio Kitamura) 29 was cloned into the EcoRI site of the retroviral vector pMSCV-neo (Clontech, Mountain View, CA, USA) to generate retrovirus expression vectors. To construct mutant AML1-Evi-1, Evi-1a mutants DZF1-7, DZF8-10, DL/AS, AS/DL, D608-732 and D544-732 5, 17, 22 were digested with BlnI and NspV and inserted into the wildtype FLAG-AML1-Evi-1 to generate AE1-DZF1, AE1-DZF2, AE1-DL/AS, AE1-AS/DL, AE1-DRep, AE1-DRepDCtBP, respectively, and were cloned into pMSCV-neo. The AE1-DC-end mutant that lacks the acidic domain and the C-terminus of the AML1-Evi-1 was generated by cloning an annealed 5 0 -CGTAGCTAGC TAGCTA-3 0 oligonucleotide, which contains three-frame stops into the NspV site of the pMSCV-neo-AML1-Evi-1.
Mice
C57BL/6J mice (8-12 weeks old) were purchased from CLEA Japan (Tokyo, Japan). AML1 fl/fl Mx-cre mice (conditional AML1 knockout) 8 were maintained at C57BL/6J background before cross-mating to generate the desired genotype. Conditional knockout mice were intraperitoneally injected with 250 mg of polyinosinic-polycytidylic acid (Sigma, St Louis, MO, USA) three times on alternate days along with control littermate AML1 fl/fl (Mx1-cre non-transgenic) or AML1 wt/wt Mx-cre mice, and were used at 4-8 weeks after injection. All animal experiments were performed following the institutional guidelines for animal researches. Leukemogenic activity of AML1-Evi-1 in HSCs M Takeshita et al
Retrovirus infection of primary mouse bone marrow cells
EcoPack2-293-packaging cells (Clontech) were maintained in Dulbecco's modified Eagle's medium with 4.5 g l À1 glucose (D-6429; Sigma) supplemented with 10% fetal bovine serum (FBS) and antibiotics. To obtain retrovirus supernatants, 2 Â 10 6 packaging cells were transfected with 3 mg of vector plasmids using 9 ml of FuGene6 transfection reagent (Roche Molecular Biochemicals, Indianapolis, IN, USA). Viral supernatants were collected after 48 h of culture, filtered using 0.45-mm filters and concentrated by 4 h of centrifugation at 15 000 r.p.m. in microcentrifuge tubes.
Mice were intraperitoneally injected with 150 mg kg À1 of 5-fluorouracil (Sigma) 5 days before bone marrow collection. Mice were killed by cervical dislocation and the femora and tibiae were flushed with phosphate-buffered saline supplemented with 5% FBS, and mononuclear cells were isolated by centrifugation using Histopaque 1083 (Sigma). c-Kit þ cells were isolated with anti-CD117 magnetic beads and using the autoMACS apparatus (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's instructions. c-Kit þ cells were then resuspended in a prestimulation medium (RPMI 1640 medium supplemented with 10% FBS, 50 ng ml À1 mouse stem cell factor (PeproTech, Rocky Hill, NJ, USA), 20 ng ml À1 human thrombopoietin (generously provided by Kirin Brewery, Tokyo, Japan) and 20 ng ml À1 mouse Flt3 ligand (R&D systems, Minneapolis, MN, USA)) and were incubated in 5% CO 2 incubator for 12 h at 37 1C for prestimulation. Cells were then infected with retroviral supernatants using Retronectin (Takara Bio, Otsu, Japan) according to the manufacturer's instructions. Briefly, 24-well untreated culture plates coated with Retronectin were then coated with retroviral supernatants, target cells were loaded onto the plates at a density of 1 Â 10 4 -1 Â 10 5 cells per well and were cultured for 48 h. Viral supernatants were added on day 1 of culture to enhance infection efficiency.
Western blotting
NIH3T3 cells were maintained in Dulbecco's modified Eagle's medium (1 g l À1 glucose) supplemented with 10% FBS and antibiotics. Cells seeded onto the six-well tissue culture plate on the prior day of infection were infected with 1 ml of retroviral supernatants and 8 mg ml À1 of polybrene. Forty-eight hours after infection, cells were lysed, fractionated by 6.5% SDS-polyacrylamide gel electrophoresis, transferred to a polyvinylidene diflouride membrane and were detected using anti-FLAG M2 monoclonal antibody (Sigma) and the ECL system (GE Healthcare, Little Chalfont, England).
Flow cytometric analyses and sorting of the myeloid progenitors c-Kit
þ bone marrow cells were collected as described above from C57BL/6J mice without 5-fluorouracil treatment and stained with fluorescein isothiocyanate-conjugated antibody to CD34, phycoerythrin-conjugated antibody to FcgR III/II, PE-Cy7-conjugated antibody to Sca-1 and biotin-conjugated antibody to lineage-specific antigens (Lin; CD3e, CD4, CD8a, Mac-1, Gr-1, Ter119 and B220), followed by visualization with PerCP-streptavidin. Dead cells were co-stained with 7-AAD (Via-Probe; BD Biosciences, San Jose, CA, USA) and removed from the sorting gate along with lineagepositive cells. For staining cells in the semisolid cultures, cells collected and washed twice with phosphate-buffered saline were stained similarly with the same antibodies, or with 7-AAD and fluorescein isothiocyanate-conjugated antibody to Mac-1. Antibodies were purchased from BD Biosciences. Stained cells were analyzed and sorted using BD FACSAria (BD Biosciences) cell sorter. For retroviral infection experiments, sorted cells were infected with retrovirus following the same protocol as c-Kit þ cells. Data were analyzed using the FACSDiva software (BD Biosciences).
Colony replating assay for the retrovirus-infected bone marrow cells
Retrovirus-infected cells were collected, washed with phosphatebuffered saline, resuspended in Iscove's modified Dulbecco's medium supplemented with 2% FBS and cultured in Methocult M3434 (Stem Cell Technologies, Vancouver, British Columbia, Canada) supplemented with 10 ng ml À1 mouse granulocytemacrophage colony-stimulating factor (R&D Systems) and 0.8 mg ml À1 G418 at a density of approximately 1 Â 10 5 cells per 35-mm plate. Colonies were scored at day 9 or 10 of the initial culture, and all cells from the semisolid medium were collected and washed twice in phosphate-buffered saline and cultured at 1 Â 10 5 (AML1-Evi-1-mutant assays, in which infection efficiencies were relatively low) or 2 Â 10 4 (other assays) per plate again in the same semisolid medium without G418. Colony scoring and replating were repeated every 7 days for at least four times, or until no colonies were observed in the cultures. In experiments using conditional AML1-knockout animals, cells from the second replating cultures were genotyped by genomic PCR using the primers f2, r1 and f120, as described previously. 8 
Results
Deletion of the functional domains of Evi-1 impairs AML1-Evi-1-induced transformation of the c-Kit þ mouse bone marrow cells
We have previously shown that the Evi-1 sequence of AML1-Evi-1 is essential for its transforming activity using Rat1 fibroblasts. 30 When introduced into primary murine bone marrow cells, AML1-Evi-1 can induce leukemia in the transplanted mice. 25 In recent reports, the CtBP-binding domain and the second zinc-finger domain, the latter of which stimulates activator protein-1 activity and is required for transformation of Rat1 fibroblasts, are also required for transformation of primary murine bone marrow cells by AML1-Evi-1. 15, 31 To assess whether other functional domains of Evi-1 are required for the transforming activity of AML1-Evi-1, we constructed MSCV-based retrovirus constructs that express the two major isoforms of Evi-1 (Evi-1a and Evi-1c) or the AML1-Evi-1 mutants together with the neomycin resistance gene (Figure 1a ). AE1-DZF1 and AE1-DZF2 lack the first and the second zinc-finger domain, respectively. The CtBP-binding motif is mutated in AE1-DL/AS, which results in loss of CtBP binding, whereas AE1-AS/DL is a mutant that retains the CtBPbinding capacity; 24 AE1-DRep and AE1-DRepDCtBP lack the repression domain that is required for repression of transforming growth factor-b signaling, and the region containing the CtBPbinding motif together with the repression domain, respectively. The C-terminal acidic domain is deleted in AE1-DC-end (Figure 1a) . The protein expression of the infected NIH3T3 cells was confirmed by western blotting (Figure 1b) . Bone marrow cells from 5-fluorouracil-treated mice were sorted for c-Kit expression by immunomagnetic beads, and were infected by viral supernatants containing each construct, selected in a G418-containing semisolid medium and were subjected to colony replating assays ( Figure 2a) . As shown in Figure 2b , bone marrow cells that express AML1-Evi-1 show prolonged growth for at least four rounds of replating, whereas cells infected with control virus expressing neomycin resistance gene alone disappear by the third round of replating. As was already reported, Evi-1a, Evi-1c or AML1-Evi-1 mutants that lack CtBPbinding capacity or the second zinc-finger domain did not transform bone marrow cells (Figure 2b ). In contrast, amino-acid substitution in AE1-AS/DL that spares CtBP binding did not affect transformation (Figure 2b) . Remarkably, AML1-Evi-1 mutants that lack the first zinc-finger domain, the repression domain or the C-terminal acidic domain did not confer replating capacity on the bone marrow cells, suggesting that these domains are also required for the transforming activity of AML1-Evi-1.
Fusion of AML1 and Evi-1 is required for transformation of bone marrow cells
Although we have demonstrated that the entire sequence of Evi-1 is required for transformation of primary bone marrow cells by AML1-Evi-1, it remained unclear whether recruitment of Evi-1 to AML1-binding DNA sequences or functional synergism between repression of AML1 and activation of Evi-1 is essential for AML1-Evi-1-induced cellular transformation. To address this issue, we used the mutant mice in which AML1 is inactivated in adult bone marrow cells. 8 Bone marrow cells were collected from adult AML1 fl/fl , Mx-cre mice and littermate control mice (AML1 fl/fl , Mx-cre non-transgenic or AML1 wt/wt , Mx-cre) treated with polyinosinic-polycytidylic acid, and were subjected to the colony replating assay using Evi-1a, Evi-1c and MLL-ENLexpressing retrovirus (Figure 3a) . Our prior observation showed that the AML1-deleted bone marrow cells survive several rounds of replating; however, these cells eventually cease to grow. 8 Consistently, AML1-deleted cells that were infected with control virus showed elongated but limited replating compared with control cells (Figure 3b ). MLL-ENL, which transforms normal bone marrow cells, could also transform the AML1-deleted bone marrow cells (Figure 3b ). As we have described previously, 8 the AML1 allele was efficiently deleted in these culture experiments (Figure 3c) . Interestingly, forced expression of Evi-1a or Evi-1c 
AML1-Evi-1 transforms the most immature hematopoietic cells
It has been reported that a class of leukemia-related genes, including MLL-ENL, can transform the myeloid-restricted common myeloid progenitors (CMPs) and the granulocytemacrophage progenitors (GMPs), as well as the c-Kit þ Sca-1 þ Lin À population, which contains the HSCs (KSL), 26 suggesting that they provide de novo self-renewal activity to committed progenitor cells. We sought to determine whether AML1-Evi-1 converts the committed progenitors into self-renewing transformed cells or causes transformation exclusively in HSCs with intrinsic self-renewal activity. We purified the KSL, CMP and GMP fractions using flow cytometry and subjected these cells to colony replating assay using AML1-Evi-1, MLL-ENL and AML1-ETO (Figures 4a and b) . Consistent with the earlier report, 26 MLL-ENL could transform CMP and GMP cells in addition to KSL cells (Figure 4c ). AML1-ETO, which represses normal AML1 function as well as AML1-Evi-1, also could transform the KSL, CMP and GMP fractions (Figure 4c ). In contrast, AML1-Evi-1 could transform only the KSL fraction, and CMPs and GMPs did not show extended replating when AML1-Evi-1 was introduced (Figure 4c ). These results indicate that intrinsic mechanisms of the KSL cells are required for the transforming activity of AML1-Evi-1, and that chimeric partners fused to AML1 determine target cell fractions susceptible to transformation. We collected the . These results again demonstrate that transforming properties of AML1-ETO and AML1-Evi-1 are different, and the fusion partners of AML1 determine the characteristics of the transformed cells.
Discussion
Our results show that the multiple functional domains of AML1-Evi-1 are required for transformation of murine bone marrow progenitor cells. It is suggested that these domains are also required for in vivo leukemogenic activity, because only the cells transduced with oncogenes that have in vitro replating capacity can develop leukemia in vivo. 27, 32 It was previously reported that the second zinc-finger domain and the CtBPbinding motif are required for the transforming activity of AML1-Evi-1, suggesting that activation of activator protein-1 and recruitment of CtBP to the AML1-binding sequence are required for the transforming activity of AML1-Evi-1. 15, 31 In our current experiments, AML1-Evi-1 mutants that lack the first zinc-finger domain, or the repression domain, do not have transforming activity, suggesting that the biological processes employed by these regions are also required for the transforming activity of AML1-Evi-1. These regions are responsible for repression of transforming growth factor-b signaling 17 or inhibition of c-Jun N-terminal kinase, 18 which may also be related with abnormal growth and immortalization. In addition, we revealed an indispensable role for the C-terminal acidic domain in transforming activity of AML1-Evi-1, whose function has not been well defined thus far. Taken together, the transforming activity of AML1-Evi-1 should be brought through complex and delicate processes exerted by Evi-1.
Loss of AML1 function in adult bone marrow cells results in accumulation of hematopoietic stem/progenitor cells; 8 however, it is not sufficient for leukemia development in AML1-null mice. Since AML1-Evi-1 shares several molecular processes with wildtype Evi-1, and AML1 is more widely expressed in hematopoietic cells than Evi-1, formation of AML1-Evi-1 causes activation of Evi-1 function in hematopoietic cells, resulting in enhanced cellular proliferation. In our current experiments, however, forced Evi-1 expression in AML1-null cells did not enhance replatability of bone marrow cells, suggesting that the transforming activity of AML1-Evi-1 does not merely depend on the synergistic effect of impaired AML1 and activated Evi-1, but also on a gain of function employed by the fusion of AML1 and Evi-1, such as recruitment of Evi-1 to the vicinity of PEBP2-binding sequences. 24 Chimeric proteins found in leukemias may immortalize target cells by activating self-renewal programs de novo, or by using intrinsic self-renewal programs. We observed that AML1-ETO could transform not only KSL but also CMPs and GMPs, as is the case with MLL-ENL. In contrast, AML1-Evi-1 exclusively transforms KSL. This observation suggests that the transforming activity of AML1-Evi-1 is dependent on self-renewal capacity intrinsic to the HSCs that are usually lost in a short time along with differentiation in in vitro cultures, and that AML1-Evi-1 itself does not confer de novo self-renewal capacity on the committed progenitors.
In the current study, bone marrow cells transformed by AML1-Evi-1 show a myeloid-committed surface marker phenotype, whereas a major part of the cells transformed by AML1-ETO show a KSL-like surface marker phenotype. These results indicate that AML1-ETO provides committed progenitors with self-renewal capacity, resulting in generation of KSL-like transformed cells. Although AML1-Evi-1 specifically transformed the KSL fraction, the KSL phenotype was not preserved after transformation. Similar observation has been obtained for bone marrow cells transformed by MLL-ENL. Culture conditions such as high stem cell factor (c-Kit ligand) concentration in the semisolid culture may influence the surface marker phenotype of the transformed cells, although there may be other possibilities. Nevertheless, distinct phenotypes of the AML1-Evi-1-and AML1-ETO-transformed cells still suggest that there exist self-renewal programs specifically employed by the fusion partners of AML1, which awaits further investigation.
We have explicitly shown that the leukemogenic activity of AML1-Evi-1 depends on the integrity of Evi-1 fused to AML1 and requires the intrinsic self-renewal mechanisms of the HSCs. These results would be a clue to the leukemogenic activity of AML1 mutation in human leukemias, and provide a new insight to the self-renewal programs activated in human leukemias.
